UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Leukemia, 2015-07, Vol.29 (7), p.1524-1529

2015

Volltextzugriff (PDF)

P669: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3‐YEAR FOLLOW‐UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT

HemaSphere, 2022-06, Vol.6, p.567-568

2022

Volltextzugriff (PDF)

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL‐WORLD SETTINGS

HemaSphere, 2022-06, Vol.6, p.569-570

2022

Volltextzugriff (PDF)

Update on the biology of chronic lymphocytic leukemia

Current opinion in oncology, 2000-01, Vol.12 (1), p.22-29

2000

Volltextzugriff (PDF)

Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells

The Journal of immunology (1950), 1993-02, Vol.150 (4), p.1458-1470

1993

Volltextzugriff (PDF)

Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance

Journal of clinical oncology, 2003-04, Vol.21 (8), p.1466-1471

2003

Volltextzugriff (PDF)

CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Variability and genotype × cutting interactions for different nutritional components in Chenopodium album L

Horticultural science (Praha), 2006-03, Vol.33 (1), p.29-38

2006

Volltextzugriff (PDF)

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

The Journal of experimental medicine, 1990-10, Vol.172 (4), p.1217-1224

1990

Volltextzugriff (PDF)

S868 EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

HemaSphere, 2019-06, Vol.3 (S1), p.388-389

2019

Volltextzugriff (PDF)

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT‐NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

HemaSphere, 2019-06, Vol.3 (S1), p.142-n/a

2019

Volltextzugriff (PDF)

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6623-6623

2011

Volltextzugriff (PDF)

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3080-3080

2011

Volltextzugriff (PDF)

Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity

Cancer research (Chicago, Ill.), 1990-12, Vol.50 (24), p.7820-7825

1990

Volltextzugriff (PDF)

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

The Journal of experimental medicine, 1993-04, Vol.177 (4), p.1127-1134

1993

Volltextzugriff (PDF)

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3535-3535

2009

Volltextzugriff (PDF)

Immunotherapy of prostate cancer in the dunning rat model : use of cytokine gene modified tumor vaccines

Cancer research (Chicago, Ill.), 1994-04, Vol.54 (7), p.1760-1765

1994

Volltextzugriff (PDF)

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3532-3532

2008

Volltextzugriff (PDF)

Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone

Leukemia & lymphoma, 2005-04, Vol.46 (4), p.635-637

2005

Volltextzugriff (PDF)

Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

International journal of cancer, 1993-02, Vol.53 (3), p.471-477

1993

Volltextzugriff (PDF)

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

The Journal of immunology (1950), 1994-03, Vol.152 (5), p.2324-2332

1994

Volltextzugriff (PDF)

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs

Blood, 1994-03, Vol.83 (5), p.1289-1298

1994

Volltextzugriff (PDF)

Neutron stars and general equation of nuclear matter

Astrophysics and space science, 1982-06, Vol.84 (2), p.409-419

1982

Volltextzugriff (PDF)

Radioactive and nonradioactive bromide partition tests (BPT) in meningitis and meningoencephalitis

Journal of the Association of Physicians of India, 1983-11, Vol.31 (11), p.693

1983

Volltextzugriff (PDF)

New analytical stellar model in general relativity

Physical review. D, Particles and fields, 1983-01, Vol.27 (2), p.328-331

1983

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

ThemaLymphoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(63)
Reviews
(1)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(18)
Humans
(17)
Biological And Medical Sciences
(11)
Oncology
(11)
Medical Sciences
(9)
Animals
(8)
Male
(8)
Mice
(8)
Female
(7)
Immunotherapy
(7)
Aged
(6)
Antineoplastic Agents
(6)
Hematology
(6)
Middle Aged
(6)
Pharmacology. Drug Treatments
(6)
Transfection
(6)
Interferon-Gamma - Genetics
(5)
Prognosis
(5)
Antineoplastic Agents - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

P669: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3‐YEAR FOLLOW‐UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL‐WORLD SETTINGS

Update on the biology of chronic lymphocytic leukemia

Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells

Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance

CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS

Variability and genotype × cutting interactions for different nutritional components in Chenopodium album L

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

S868 EMERGING CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

PF381 FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT‐NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results

Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Immunotherapy of prostate cancer in the dunning rat model : use of cytokine gene modified tumor vaccines

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies

Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone

Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs

Neutron stars and general equation of nuclear matter

Radioactive and nonradioactive bromide partition tests (BPT) in meningitis and meningoencephalitis

New analytical stellar model in general relativity

Aktive Filter

Suchergebnisse filtern